Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients

Königsberg, Robert; Obermayr, Eva; Bises, Giovanna; Pfeiler, Georg; Gneist, Margit; Wrba, Fritz; Santis, Maria De; Zeillinger, Robert; Hudec, Marcus; Dittrich, Christian

doi:10.3109/0284186x.2010.549151

Cited by 212 publications

(169 citation statements)

References 18 publications

Supporting

Mentioning

163

Contrasting

Unclassified

Order By: Relevance

“…Firstly, CTCs that did not express EpCAM may have been excluded. EpCAM expression on CTCs has been debated, as cancer cells that undergo EMT lose EpCAM expression on the cell surface (12,21). Using flow cytometry, we have observed that the lung cancer PC-9 and H358 cell lines express EpCAM (unpublished data).…”

Section: Discussionmentioning

confidence: 92%

Detection of circulating tumor cells in patients with non-small cell lung cancer using a size-based platform

et al. 2017

View full text Add to dashboard Cite

Abstract. The detection of circulating tumor cells (CTCs) is limited by the rarity of these cells in the peripheral blood of patients with cancer. Understanding tumor biology may be useful in the development of novel therapeutic strategies for patients with lung cancer. The present study evaluated a novel size-based filtration platform for enriching CTCs from patients with lung cancer. Blood samples were obtained from 82 patients with lung cancer for CTC analysis. CTC enrichment by size-based filtration was performed on 5-ml blood samples. The collected cells were detected by immunofluorescence using monoclonal anti-human antibodies against protein tyrosine phosphatase, receptor type C (CD45) and epithelial cell adhesion molecule (EpCAM; an epithelial cell marker), as well as a DAPI nucleic acid stain. CTCs were detected in 57 patients (69.5%) using the size-based filtration platform. The mean CTC counts, defined as the number of cells with DAPI-positive, CD45-negative and EpCAM-positive staining, were 1.48±1.71 per 5 ml blood for the 66 stage I-III patients and 8.00±9.95 per 5 ml blood for the 16 stage IV patients. The presence of ≥1 CTCs per 5-ml blood sample was significantly associated with pathological stage (stage IV vs. stage I-III, P=0.009), but not with patient age or gender, tumor histology, tumor size or lymphovascular invasion. The mean CTC count of healthy donors was 0.25±0.55 per 5 ml blood. In summary, CTCs from the blood of patients with lung cancer were enriched using a size-based filtration platform and immunofluorescent staining with DAPI, CD45 and EpCAM. The CTC counts of patients with stage IV cancer were higher than those of patients with stages I-III cancer. These results suggest that this novel platform may be a useful tool for determining the prognosis of patients with lung cancer.

show abstract

Section: Discussionmentioning

confidence: 92%

Detection of circulating tumor cells in patients with non-small cell lung cancer using a size-based platform

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Only CTC that express EpCAM as well as Cytokeratin 8, 18, or 19 will be detected by this system. The frequency and the relation to clinical outcome of CTC that do not express these antigens are being explored through a variety of alternative approaches for the detection of CTC (53)(54)(55)(56)(57)(58)(59)(60). Although only viable CTC will have the potential to form metastasis, the presence of apoptotic CTC or CTC debris might also be an indicator of a worse prognosis.…”

Section: Ckmentioning

confidence: 99%

Automated identification of circulating tumor cells by image cytometry

Scholtens

Schreuder

Ligthart³

et al. 2011

Cytometry Pt A

View full text Add to dashboard Cite

Presence of circulating tumor cells (CTC), as detected by the CellSearch 1 System, in patients with metastatic carcinomas is associated with poor survival prospects. CellTracks TDI, a dedicated image cytometer, was developed to improve the enumeration of these rare CTC. The CellSearch System was used to enumerate CTC in 7.5 mL blood of 68 patients with cancer and 9 healthy controls. Cartridges containing the fluorescently labeled CTC from this system were reanalyzed using the image cytometer, which acquires images with a TDI camera using a 403/0.6 NA objective and lasers as light source. Automated classification of events was performed by the Random Forest method using Matlab. An automated classifier was developed to classify events into CTC, apoptotic CTC, CTC debris, leukocytes, and debris not related to CTC. A high agreement in classification was obtained between the automated classifier and five expert reviewers. Comparison of images from the same events in CellTracks TDI and CellTracks Analyzer II shows improved resolution in fluorescence images and improved classification by adding bright-field images. Improved detection efficiency for CD45-APC avoids the classification of leukocytes nonspecifically binding to cytokeratin as CTC. The correlation between number of CTC detected in CellTracks TDI and CellTracks Analyzer II is good with a slope of 1.88 and a correlation coefficient of 0.87. Automated classification of events by CellTracks TDI eliminates the operator error in classification of events as CTC and permits quantitative assessment of parameters. The clinical relevance of various CTC definitions can now be investigated. '

show abstract

“…In one study, about 2/3 of TNBCs, presumably the basal-like subtype, stained strongly for EpCAM (25). The number of EpCAM þ circulating cells is linked to poor prognosis in breast cancer (32)(33)(34)(35)(36). An EpCAM antibody has been evaluated clinically for epithelial cancers, but had limited effectiveness on its own (37)(38)(39).…”

Section: Introductionmentioning

confidence: 99%

Gene Knockdown by EpCAM Aptamer–siRNA Chimeras Suppresses Epithelial Breast Cancers and Their Tumor-Initiating Cells

Gilboa-Geffen

Hamar

et al. 2015

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

show abstract

Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients

Cited by 212 publications

References 18 publications

Detection of circulating tumor cells in patients with non-small cell lung cancer using a size-based platform

Detection of circulating tumor cells in patients with non-small cell lung cancer using a size-based platform

Automated identification of circulating tumor cells by image cytometry

Gene Knockdown by EpCAM Aptamer–siRNA Chimeras Suppresses Epithelial Breast Cancers and Their Tumor-Initiating Cells

Contact Info

Product

Resources

About